SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)
$A
Biotechnology: Laboratory Analytical Instruments
Industrials
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $135.00 → $145.00 | Underweight → Equal Weight | Barclays |
| 8/28/2024 | $157.00 | Overweight | Wells Fargo |
| 7/10/2024 | $135.00 → $150.00 | Neutral → Buy | Citigroup |
| 6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/3/2024 | $135.00 | Hold | Jefferies |
| 4/5/2024 | $145.00 → $163.00 | Hold → Buy | Stifel |
| 12/13/2023 | $140.00 | Outperform | Wolfe Research |
| 12/12/2023 | $130.00 → $133.00 | Buy → Neutral | BofA Securities |
Center of Excellence will feature bio-environmental research to facilitate advancements in environmental health and safety Agilent Technologies Inc. and Georgia Tech today announced the establishment of an Agilent Center of Excellence (CoE) for Environmental Health and Engineering to advance research in environmental sustainability, water recycling, and biologics. Internationally recognized environmental scientist Professor Shane Snyder from the School of Civil and Environmental Engineering at Georgia Tech will lead the Agilent CoE. The CoE will foster collaboration and innovation among researchers, serve as a hub for innovation in environmental characterization, and integrate Agilent's
Agilent Technologies Inc. (NYSE:A) today announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume, workflow, and diagnostic requirements. With the launch of the Agilent Dako Omnis family, Agilent transitions beyond a one-size-fits-all model to offer a tailored portfolio—empowering labs to select the configuration that best meets their needs. Scalable Solutions for Every Lab—From Routine to Revolutionary. Dako Omnis 110: Built fo
Following an announcement earlier this week, Agilent Technologies Inc. (NYSE:A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes on Wednesday, Aug. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innova
8-K/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
144 - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously
Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00
Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p
Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Following an announcement earlier this week, Agilent Technologies Inc. (NYSE:A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes on Wednesday, Aug. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innova
Agilent Technologies Inc. (NYSE:A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East Coast for family reasons and prepares for the next chapter in his career. Following McMahon's departure, Rodney Gonsalves, Agilent's current corporate controller and principal accounting officer, will additionally serve as interim CFO until McMahon's successor is named. "I want to sincerely thank Bob for his seven impactful years of service at Agilent. His leadership and contributions have played an important role in our company's growth, and we wish him the best in his future endeavors," said Pr
Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)